Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply

G Heller; R McCormack; T Kheoh; A Molina; MR Smith; R Dreicer; F Saad; Ronald de Wit; DT Aftab; M Hirmand; A Limon-Carrera; K Fizazi; M Fleisher; JS de Bono; HI Scher

doi:10.1200/jco.2018.78.2672

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply

G Heller
, R McCormack
, T Kheoh
, A Molina
, MR Smith
, R Dreicer
, F Saad
, Ronald de Wit
, DT Aftab
, M Hirmand
, A Limon-Carrera
, K Fizazi
, M Fleisher
, JS de Bono
, HI Scher

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2354-2355
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	36
Issue number	22
DOIs	https://doi.org/10.1200/jco.2018.78.2672
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-08

Access to Document

10.1200/jco.2018.78.2672

http://hdl.handle.net/1765/109666

Cite this

Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, MR., Dreicer, R., Saad, F., de Wit, R., Aftab, DT., Hirmand, M., Limon-Carrera, A., Fizazi, K., Fleisher, M., de Bono, JS., & Scher, HI. (2018). Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply. Journal of Clinical Oncology, 36(22), 2354-2355. https://doi.org/10.1200/jco.2018.78.2672

@article{85845653b08d4ebaa916e95e976e65c3,

title = "Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply",

author = "G Heller and R McCormack and T Kheoh and A Molina and MR Smith and R Dreicer and F Saad and \{de Wit\}, Ronald and DT Aftab and M Hirmand and A Limon-Carrera and K Fizazi and M Fleisher and \{de Bono\}, JS and HI Scher",

year = "2018",

doi = "10.1200/jco.2018.78.2672",

language = "Undefined/Unknown",

volume = "36",

pages = "2354--2355",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "22",

}

Heller, G, McCormack, R, Kheoh, T, Molina, A, Smith, MR, Dreicer, R, Saad, F, de Wit, R, Aftab, DT, Hirmand, M, Limon-Carrera, A, Fizazi, K, Fleisher, M, de Bono, JS & Scher, HI 2018, 'Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply', Journal of Clinical Oncology, vol. 36, no. 22, pp. 2354-2355. https://doi.org/10.1200/jco.2018.78.2672

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply. / Heller, G; McCormack, R; Kheoh, T et al.
In: Journal of Clinical Oncology, Vol. 36, No. 22, 2018, p. 2354-2355.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply

AU - Heller, G

AU - McCormack, R

AU - Kheoh, T

AU - Molina, A

AU - Smith, MR

AU - Dreicer, R

AU - Saad, F

AU - de Wit, Ronald

AU - Aftab, DT

AU - Hirmand, M

AU - Limon-Carrera, A

AU - Fizazi, K

AU - Fleisher, M

AU - de Bono, JS

AU - Scher, HI

PY - 2018

Y1 - 2018

U2 - 10.1200/jco.2018.78.2672

DO - 10.1200/jco.2018.78.2672

M3 - Article

SN - 0732-183X

VL - 36

SP - 2354

EP - 2355

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -